ITK

New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

Retrieved on: 
월요일, 12월 13, 2021
T-cell lymphoma, Forward-looking statement, U.S. Securities and Exchange Commission, Gastrointestinal tract, NK, Lymphatic system, Poster, Company, Doctor of Philosophy, ITK, Biomarker, CD73, COVID-19, Time, Haematopoietic system, NASDAQ, Survival, Sickle cell disease, Pharmacokinetics, Memorial Sloan Kettering Cancer Center, Liver, Safety, Patient, Leukemia, Security (finance), Steroid, Bone marrow, Hemoglobinopathy, A2A, Immunodeficiency, MD, GLOBE, ASH, Interim, Division, Hematopoietic stem cell transplantation, Antigen, Skin, Mouse, Society, Head, Pharmaceutical industry, Vaccine, Degenerative disease, Corvus, GVHD

The data will be presented today in a poster at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition.

Key Points: 
  • The data will be presented today in a poster at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition.
  • Bone marrow transplantation is a potentially curative therapy for patients with a variety of blood disorders, including blood cancers, certain solid cancers, hemoglobinopathies such as sickle cell disease, and immune deficiencies.
  • Recipient mice were pre-conditioned by having their bone marrow ablated with high dose radiation, and then received an allogeneic bone marrow transplantation.
  • This preclinical data suggests that ITK inhibition with CPI-818 has the potential to be a novel agent that could prevent or treat aGVHD.

Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Retrieved on: 
수요일, 11월 10, 2021
A2A, T-cell lymphoma, ITK, NASDAQ, Conference, Company, GLOBE, CD73, Webcast, Patient, Vaccine

BURLINGAME, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies London Healthcare Conference, which is taking place November 16-19, 2021.

Key Points: 
  • BURLINGAME, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies London Healthcare Conference, which is taking place November 16-19, 2021.
  • A webcast of the presentation will be available via the investor relations section of the Corvus website for 30 days following the event.
  • Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
  • Corvus lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies.

Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 American Society of Hematology Annual Meeting

Retrieved on: 
목요일, 11월 4, 2021
Safety, Annual general meeting, Research, 2021 Essex County Council election, Poster, SAN, BTK, Industry, HDAC, CAR, Patient, Private Securities Litigation Reform Act, Lymphoma, Nasopharyngeal carcinoma, SEC, ASH, Government, Communication, Time, Risk, ITK, COVID-19, EBV, Nodular lymphocyte predominant Hodgkin lymphoma, Nasdaq, Therapy, Toxicity, Society, Pharmaceutical industry, Vaccine

"Having three abstracts accepted at ASH is an honor that we believe speaks to the innovative nature of our growing pipeline.

Key Points: 
  • "Having three abstracts accepted at ASH is an honor that we believe speaks to the innovative nature of our growing pipeline.
  • We look forward to the meeting in December and are excited to share more about these programs following the presentations."
  • Copies of the poster and oral presentations will be available on the "Events and Webcasts" section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts following their presentation at the meeting.
  • Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.

Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
화요일, 11월 2, 2021
CD73, T-cell lymphoma, Patient, NSCLC, Lymphocyte, Immunity, ITK, Cancer, Webcast, Neoplasm, A2A, Vaccine

The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) and using the conference ID 13724618.

Key Points: 
  • The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) and using the conference ID 13724618.
  • The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website.
  • A replay of the webcast will be available on Corvus' website for 90 days.
  • Mupadolimab (CPI-006) is an investigational, potent humanized monoclonal antibody that is designed to react with a specific site on CD73.

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

Retrieved on: 
월요일, 11월 1, 2021
Safety, Head, RCC, Neoplasm, HPV, Partnership, Adenosine, Society, NMPA, CDE, Degenerative disease, Clinical trial, COVID-19, IND, Program, HPV-positive oropharyngeal cancer, Extranodal NK/T-cell lymphoma, nasal type, ATP, Immune system, Autoimmunity, GLOBE, SITC, Kidney cancer, Antigen, Tumor microenvironment, Death, BTK, Total, Leukemia, Security (finance), T-cell lymphoma, Company, Investment, ITK, EBV, Immunotherapy, Virus, Large-cell lung carcinoma, Exercise, Center, Immunity, HNSCC, A2A, Nasdaq, Sale, Pembrolizumab, Board of directors, NSCLC, Cancer, Patient, Lymphocyte, Time, Forward-looking statement, NK, CD73, Research, Pharmaceutical industry, Vaccine

BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2021.

Key Points: 
  • BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2021.
  • We anticipate that the results will be presented at the annual meeting of the Society of Immunotherapy of Cancer (SITC) in November 2021.
  • The endpoint of the clinical trial is response rate and initial results are anticipated in 2022.
  • Angel Pharmaceuticals was launched through a collaboration with U.S.-based Corvus Pharmaceuticals and investments from investors in China.

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

Retrieved on: 
수요일, 10월 27, 2021
Safety, TCL, Cancer, BTK, A2A, Leukemia, Securities and Exchange Commission (Philippines), Patient, Security (finance), NMPA, T-cell lymphoma, Interim, ASH, Lymphoma, Degenerative disease, Time, Center, CDE, Forward-looking statement, ITK, Company, Investment, Antigen, Clinical trial, Biomarker, COVID-19, National Medical Products Administration, NK, Board, CD73, IND, Pharmacokinetics, Center for Drug Evaluation and Research, Nasdaq, Autoimmunity, GLOBE, Prevalence, Incidence, Society, Board of directors, Pharmaceutical industry, Fine chemical, Vaccine

Corvus co-founded Angel Pharma to develop its pipeline in greater China and currently holds an equity stake of 49.7% in the company.

Key Points: 
  • Corvus co-founded Angel Pharma to develop its pipeline in greater China and currently holds an equity stake of 49.7% in the company.
  • Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize CPI-818 in greaterChina and is responsible for all expenses related to its development in China.
  • The Angel Pharma team has been efficiently moving the development process forward and has partnered with top lymphoma clinical experts.
  • CPI-818 is an investigational, orally bioavailable, covalent inhibitor of ITK designed to have low nanomolar affinity.

New report explores risk factors for high rates of suicide, substance use among Inuit

Retrieved on: 
수요일, 10월 13, 2021
Risk, Suicide, Food, Substance, Cannabis, ITK, Statistics, Knowledge, Housing, Protective factor, Education, Parliament, Center, Health, Data collection, GLOBE, Truth and Reconciliation Commission (South Africa), Mental health, Health Canada, Truth, Indigenous self-government in Canada, CEO, CCSA, Research, Hope, Truth and Reconciliation Commission of Canada, Whaling, Medicine

The Canadian Centre on Substance Use and Addiction (CCSA) and Inuit Tapiriit Kanatami (ITK), the national organization representing Inuit across Canada, have released Substance Use, Mental Health and Suicide among Inuit in Canada , which summarizes the latest statistics on substance use and mental health among Inuit.

Key Points: 
  • The Canadian Centre on Substance Use and Addiction (CCSA) and Inuit Tapiriit Kanatami (ITK), the national organization representing Inuit across Canada, have released Substance Use, Mental Health and Suicide among Inuit in Canada , which summarizes the latest statistics on substance use and mental health among Inuit.
  • Inuit have some of the highest suicide rates in Canada, with rates in some Inuit regions being 25 times higher than the Canadian average.
  • The report identifies additional risk factors, such as community distress, mental health conditions, substance use and socioeconomic inequities.
  • The findings underline the importance of having an Inuit health survey governed and led by Inuit to ensure data reflect Inuit health and wellness accurately.

Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Retrieved on: 
화요일, 9월 7, 2021

BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Companys management will participate in two upcoming investor conferences in September:

Key Points: 
  • BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Companys management will participate in two upcoming investor conferences in September:
    The first conference is the H.C. Wainwright Annual Global Investment Conference, which is taking place September 13-15, 2021.
  • The second conference is the Cantor Virtual Global Healthcare Conference, which is taking place September 27-30, 2021.
  • Attendees can also access the webcast of the presentations noted above via the investor relations section of the Corvus website and replays will be available for 90 days following the events.
  • Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor.

Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China

Retrieved on: 
월요일, 8월 16, 2021
Time, Forward-looking statement, Center, Degenerative disease, Securities and Exchange Commission (Philippines), T-cell lymphoma, Autoimmunity, ITK, Leukemia, CMC, ASH, A2A, Interim, PTCL, Clinical trial, CDE, Biomarker, National Medical Products Administration, Company, CD73, BTK, COVID-19, NK, IND, Antigen, GLOBE, NMPA, Pharmacokinetics, Research, Center for Drug Evaluation and Research, Security (finance), Board, Patient, Pharmacovigilance, Molecular biology, Investment, Board of directors, Cancer, Nasdaq, Pharmacology, Safety, Chemistry, Society, Extranodal NK/T-cell lymphoma, nasal type, Prevalence, Pharmaceutical industry, Fine chemical, Vaccine

Angel Pharma plans to initiate the trial before the end of 2021 and will be responsible for all expenses related to executing the trial in China.

Key Points: 
  • Angel Pharma plans to initiate the trial before the end of 2021 and will be responsible for all expenses related to executing the trial in China.
  • CPI-818 is the first-and-only clinical stage ITK-inhibitor in China and we believe that Angel Pharma is well-positioned to accelerate its development for this market and globally.
  • Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize CPI-818 in greater China.
  • Angel Pharma was launched through a collaboration with U.S.-based Corvus Pharmaceuticals and investments from investors in China.

Government of Canada announces $340 million to support Indigenous-led conservation

Retrieved on: 
목요일, 8월 12, 2021
Knowledge, Colonialism, Climate change, Inuit Nunangat, Indigenous self-government in Canada, ITK, Indigenous peoples, Environment, Biodiversity, MTI Home Video, Science, Partnership, IPCA, Tradition, Nature, Health, Investment, Government, First Nations, Leadership, Ice, Indigenous and community conserved area, Biodiversity loss, Education, Parks Canada, Park, Whaling, Agriculture

From this funding, up to $173 million will fund new and existing Indigenous Guardians initiatives and the development of Indigenous Guardians Networks for First Nations, Inuit and Mtis.

Key Points: 
  • From this funding, up to $173 million will fund new and existing Indigenous Guardians initiatives and the development of Indigenous Guardians Networks for First Nations, Inuit and Mtis.
  • Indigenous Guardians initiatives support Indigenous peoples in protecting and conserving the environment, developing and maintaining sustainable economies, and continuing the profound connections between Indigenous cultures and their lands.
  • The Government of Canada will also work with Indigenous partners at Parks Canadaadministered places to enhance current Guardian initiatives and co-create new ones.
  • Since 2018, the Indigenous Guardians Pilot has invested over $20 million in more than eighty initiatives across the country.